title: Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication.
abstract: One hundred and one patients undergoing anticancer chemotherapy due to hematologic malignancy were retrospectively divided into two groups: 67 patients were treated with ceftriaxone plus amikacin, receiving once daily (od) 2-4 g ceftriaxone, 1-1.5 g amikacin (those without a peripheral or central venous catheter) and 34 patients with central or peripheral venous catheter (CPVC) receiving ceftizidime 2 g three times daily (tid) plus amikacin 0.5 g tid i.v. Both groups were similar as to their isolated pathogens, localization of infection, and basic diagnoses of hematologic malignancies. There was no significant difference in efficacy between ceftriaxone plus amikacin versus ceftazidime plus amikacin, but the toxicity was lower in once daily ceftriaxone plus amikacin group.
authors.affiliation: Department of Clinical Oncology, Postgraduate Medical School, Bratislava, Slovakia.
authors.forename: V
authors.initials: V
authors.lastname: Krcméry
authors.forename: A
authors.initials: A
authors.lastname: Danisovicová
authors.forename: L
authors.initials: L
authors.lastname: Drgona
authors.forename: S
authors.initials: S
authors.lastname: Spánik
authors.forename: P
authors.initials: P
authors.lastname: Fuchsberger
authors.forename: S
authors.initials: S
authors.lastname: Korec
authors.forename: J
authors.initials: J
authors.lastname: Svec
mesh_terms: D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002177:Candidiasis / Q000188:drug therapy / Q000209:etiology; D002405:Catheterization, Central Venous; D002406:Catheterization, Peripheral; D002442:Ceftazidime / Q000009:adverse effects / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use; D006309:Hearing / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007938:Leukemia / Q000150:complications / Q000188:drug therapy; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications* / Q000209:etiology; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D002443:Ceftriaxone; D000583:Amikacin; D002442:Ceftazidime